Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,543 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Women-Only Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

NCT03076970
View directory record Official record
Conditions
Migraine
Interventions
lasmiditan 200 mg, Sumatriptan, matching placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Functionality of Female Condom With a Silicone Elastomer Vaginal Ring

NCT01755754
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Silicone Elastomer Vaginal Ring, Female Condom
Combination Product · Device
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 15, 2026, 1:04 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age

NCT04092387
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Varying the nicotine content of cigarettes, E-Cigarettes
Other
Lead sponsor
University of Vermont
Other
Eligibility
21 Years to 44 Years · Female only
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

NCT04779216
View directory record Official record
Conditions
Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
Interventions
Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg
Drug
Lead sponsor
Karen Klahr Miller, MD
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Not applicable Interventional Results available

Metabolic Study of Sleep Apnea in Men and Women

NCT00706511
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
CPAP
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions

NCT01330199
View directory record Official record
Conditions
Healthy Adult Females
Interventions
Pharmacokinetic Sampling
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 15, 2026, 1:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

NCT03036930
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

NCT03272165
View directory record Official record
Conditions
Parkinson's Disease
Interventions
MEDI1341, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 15, 2026, 1:04 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

NCT00880009
View directory record Official record
Conditions
Breast Cancer
Interventions
Bosutinib, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Whittier, California • Joliet, Illinois • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glucose Management Among Women With Gestational Diabetes Mellitus

NCT02596932
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Standard Protocol for intrapartum glucose management, Experimental Protocol for intrapartum glucose management
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 15, 2026, 1:04 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 15, 2026, 1:04 PM EDT
Not listed Phase 3 Interventional Results available

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

NCT00108745
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel, Paclitaxel Poliglumex, Quality-of-Life Assessment
Other · Drug · Procedure
Lead sponsor
GOG Foundation
Network
Eligibility
Female only
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
315
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 228 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 15, 2026, 1:04 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Real-World Evidence Study Evaluating the Effects of the Human Optimization Project Protocol on Methylation Biomarkers and Health-Related Quality of Life in Women

NCT07548645
View directory record Official record
Conditions
Longevity, Women's Health
Interventions
Human Optimization Project
Dietary Supplement
Lead sponsor
Human Optimization Project
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 15, 2026, 1:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Normative Movement Analysis Data Collection

NCT04638595
View directory record Official record
Conditions
Pediatric ALL
Interventions
Observation
Other
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
3 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Puyallup, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 15, 2026, 1:04 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of Hysterotomy Site After Open Fetal Surgery

NCT02493062
View directory record Official record
Conditions
Myelomeningocele, Pregnancy
Interventions
Sonohysterogram
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women

NCT00620854
View directory record Official record
Conditions
Osteoporosis
Interventions
Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

NCT04890561
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lemborexant
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women

NCT02357602
View directory record Official record
Conditions
Healthy
Interventions
GS-7340
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

NCT00002920
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer
Interventions
medroxyprogesterone, tamoxifen citrate, adjuvant therapy
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
122
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

NCT03698305
View directory record Official record
Conditions
Healthy Subjects
Interventions
ASP5354, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 15, 2026, 1:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Lu AG06474 in Healthy Young Participants

NCT05943327
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AG06474, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 15, 2026, 1:04 PM EDT
Completed No phase listed Observational

Delphinus SoftVue™ ROC Reader Study

NCT03972605
View directory record Official record
Conditions
Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
Interventions
Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 15, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

NCT03471663
View directory record Official record
Conditions
Breast Cancer
Interventions
D-0502, palbociclib
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Fresno, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 15, 2026, 1:04 PM EDT